Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Effectiveness of CoronaVac, ChAdOx1, BNT162b2 and Ad26.COV2.S among individuals with prior SARS-CoV-2 infection in Brazil

View ORCID ProfileThiago Cerqueira-Silva, Jason R. Andrews, Viviane S. Boaventura, Otavio T. Ranzani, Vinicius de Araújo Oliveira, Enny S Paixão, Juracy Bertoldo Júnior, Tales Mota Machado, Matt D.T. Hitchings, Murilo Dorion, Margaret L Lind, Gerson O. Penna, Derek A.T. Cummings, Natalie E Dean, Guilherme Loureiro Werneck, Neil Pearce, Mauricio L. Barreto, View ORCID ProfileAlbert I. Ko, View ORCID ProfileJulio Croda, Manoel Barral-Netto
doi: https://doi.org/10.1101/2021.12.21.21268058
Thiago Cerqueira-Silva
1Instituto Gonçalo Moniz, Fiocruz, Salvador, BA, Brazil
2Universidade Federal da Bahia, Salvador, BA, Brazil
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Thiago Cerqueira-Silva
Jason R. Andrews
3Division of Infectious Diseases and Geographic Medicine, Stanford University, Stanford, CA,USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Viviane S. Boaventura
1Instituto Gonçalo Moniz, Fiocruz, Salvador, BA, Brazil
2Universidade Federal da Bahia, Salvador, BA, Brazil
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Otavio T. Ranzani
4Barcelona Institute for Global Health, ISGlobal, Barcelona, Spain
5Pulmonary Division, Heart Institute, Hospital das Clínicas, Faculdade de Medicina, São Paulo, SP, Brazil
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Vinicius de Araújo Oliveira
1Instituto Gonçalo Moniz, Fiocruz, Salvador, BA, Brazil
2Universidade Federal da Bahia, Salvador, BA, Brazil
6Center for Data and Knowledge Integration for Health - Fiocruz, Salvador, BA, Brazil
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Enny S Paixão
7London School of Hygiene and Tropical Medicine, London, United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Juracy Bertoldo Júnior
2Universidade Federal da Bahia, Salvador, BA, Brazil
6Center for Data and Knowledge Integration for Health - Fiocruz, Salvador, BA, Brazil
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tales Mota Machado
8Universidade Federal de Ouro Preto, Ouro Preto, MG, Brazil
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Matt D.T. Hitchings
9Department of Biostatistics, College of Public Health & Health Professions, University of Florida, Gainesville, FL, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Murilo Dorion
10Department of Epidemiology of Microbial Diseases, Yale School of Public Health, New Heaven, CT, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Margaret L Lind
10Department of Epidemiology of Microbial Diseases, Yale School of Public Health, New Heaven, CT, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gerson O. Penna
11Núcleo de Medicina Tropical, Universidade de Brasília, Brasília, DF, Brazil
12Escola Fiocruz de Governo, Fiocruz Brasília. Brasília, DF, Brazil
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Derek A.T. Cummings
13Department of Biology, University of Florida, Gainesville, FL, USA
14Emerging Pathogens Institute, University of Florida, Gainesville, FL, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Natalie E Dean
15Department of Biostatistics & Bioinformatics, Rollins School of Public Health, Emory University
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Guilherme Loureiro Werneck
16Universidade do Estado do Rio de Janeiro, Rio de Janeiro, RJ, Brazil
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Neil Pearce
7London School of Hygiene and Tropical Medicine, London, United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mauricio L. Barreto
2Universidade Federal da Bahia, Salvador, BA, Brazil
6Center for Data and Knowledge Integration for Health - Fiocruz, Salvador, BA, Brazil
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Albert I. Ko
1Instituto Gonçalo Moniz, Fiocruz, Salvador, BA, Brazil
10Department of Epidemiology of Microbial Diseases, Yale School of Public Health, New Heaven, CT, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Albert I. Ko
Julio Croda
10Department of Epidemiology of Microbial Diseases, Yale School of Public Health, New Heaven, CT, USA
17Universidade Federal de Mato Grosso do Sul, Campo Grande, MS, Brazil
18Fiocruz Mato Grosso do Sul, Fundação Oswaldo Cruz, Campo Grande, MS, Brazil
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Julio Croda
  • For correspondence: julio.croda{at}fiocruz.br
Manoel Barral-Netto
1Instituto Gonçalo Moniz, Fiocruz, Salvador, BA, Brazil
2Universidade Federal da Bahia, Salvador, BA, Brazil
6Center for Data and Knowledge Integration for Health - Fiocruz, Salvador, BA, Brazil
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Data/Code
  • Preview PDF
Loading

ABSTRACT

Background COVID-19 vaccines have proven highly effective among SARS-CoV-2 naive individuals, but their effectiveness in preventing symptomatic infection and severe outcomes among individuals with prior infection is less clear.

Methods Utilizing national COVID-19 notification, hospitalization, and vaccination datasets from Brazil, we performed a case-control study using a test-negative design to assess the effectiveness of four vaccines (CoronaVac, ChAdOx1, Ad26.COV2.S and BNT162b2) among individuals with laboratory-confirmed prior SARS-CoV-2 infection. We matched RT-PCR positive, symptomatic COVID-19 cases with RT-PCR-negative controls presenting with symptomatic illnesses, restricting both groups to tests performed at least 90 days after an initial infection. We used multivariable conditional logistic regression to compare the odds of test positivity, and the odds of hospitalization or death due to COVID-19, according to vaccination status and time since first or second dose of vaccines.

Findings Among individuals with prior SARS-CoV-2 infection, vaccine effectiveness against symptomatic infection ≥ 14 days from vaccine series completion was 39.4% (95% CI 36.1-42.6) for CoronaVac, 56.0% (95% CI 51.4-60.2) for ChAdOx1, 44.0% (95% CI 31.5-54.2) for Ad26.COV2.S, and 64.8% (95% CI 54.9-72.4) for BNT162b2. For the two-dose vaccine series (CoronaVac, ChAdOx1, and BNT162b2), effectiveness against symptomatic infection was significantly greater after the second dose compared with the first dose. Effectiveness against hospitalization or death ≥ 14 days from vaccine series completion was 81.3% (95% CI 75.3-85.8) for CoronaVac, 89.9% (95% CI 83.5-93.8) for ChAdOx1, 57.7% (95% CI −2.6-82.5) for Ad26.COV2.S, and 89.7% (95% CI 54.3-97.7) for BNT162b2.

Interpretation All four vaccines conferred additional protection against symptomatic infections and severe outcomes among individuals with previous SARS-CoV-2 infection. Provision of a full vaccine series to individuals following recovery from COVID-19 may reduce morbidity and mortality.

Funding Brazilian National Research Council, Fundação Carlos Chagas Filho de Amparo à Pesquisa do Estado do Rio de Janeiro, Oswaldo Cruz Foundation, JBS S.A., Instituto de Salud Carlos III, Spanish Ministry of Science and Innovation, Generalitat de Catalunya.

Evidence before this study We searched PubMed, medRxiv, and SSRN for articles published from January 1, 2020 until December 15, 2021, with no language restrictions, using the search terms “vaccine effectiveness” AND “previous*” AND (“SARS-CoV-2” OR “COVID-19”). We found several studies evaluating ChAdOx1 and BNT162b2, and one additionally reporting on mRNA-1273 and Ad26.COV2.S, which found that previously infected individuals who were vaccinated had lower risk of symptomatic SARS-CoV-2 infection. One study found that risk of hospitalization was lower for previously infected individuals after a full series of BNT162b2 or mRNA-1273. Limited evidence is available comparing effectiveness of one versus two doses among individuals with prior infection. No studies reported effectiveness of inactivated vaccines among previously infected individuals.

Added value of this study We used national databases of COVID-19 case surveillance, laboratory testing, and vaccination from Brazil to investigate effectiveness of CoronaVac, ChAdOx1, Ad26.COV2.S and BNT162b2 among individuals with a prior, laboratory-confirmed SARS-CoV-2 infection. We matched >22,000 RT-PCR-confirmed re-infections with >145,000 RT-PCR-negative controls using a test-negative design. All four vaccines were effective against symptomatic SARS-CoV-2 infections, with effectiveness from 14 days after series completion ranging from 39-65%. For vaccines with two-dose regimens, the second dose provided significantly increased effectiveness compared with one dose. Effectiveness against COVID-19-associated hospitalization or death from 14 days after series completion was >80% for CoronaVac, ChAdOx1and BNT162b2.

Implications of all the available evidence We find evidence that four vaccines, using three different platforms, all provide protection to previously infected individuals against symptomatic SARS-CoV-2 infection and severe outcomes, with a second dose conferring significant additional benefits. These results support the provision of a full vaccine series among individuals with prior SARS-CoV-2 infection.

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

Brazilian National Research Council, Fundação Carlos Chagas Filho de Amparo à Pesquisa do Estado do Rio de Janeiro, Oswaldo Cruz Foundation, JBS S.A., Instituto de Salud Carlos III, Spanish Ministry of Science and Innovation, Generalitat de Catalunya.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

All data were pseudo-anonymized with a common unique identifier provided by the Brazilian Ministry of Health. The research protocol was approved by the Brazilian National Commission in Research Ethics (CONEP) (approval number 4.921.308).

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

All data produced in the present study are available upon reasonable request to the authors

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Back to top
PreviousNext
Posted December 27, 2021.
Download PDF
Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Effectiveness of CoronaVac, ChAdOx1, BNT162b2 and Ad26.COV2.S among individuals with prior SARS-CoV-2 infection in Brazil
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Effectiveness of CoronaVac, ChAdOx1, BNT162b2 and Ad26.COV2.S among individuals with prior SARS-CoV-2 infection in Brazil
Thiago Cerqueira-Silva, Jason R. Andrews, Viviane S. Boaventura, Otavio T. Ranzani, Vinicius de Araújo Oliveira, Enny S Paixão, Juracy Bertoldo Júnior, Tales Mota Machado, Matt D.T. Hitchings, Murilo Dorion, Margaret L Lind, Gerson O. Penna, Derek A.T. Cummings, Natalie E Dean, Guilherme Loureiro Werneck, Neil Pearce, Mauricio L. Barreto, Albert I. Ko, Julio Croda, Manoel Barral-Netto
medRxiv 2021.12.21.21268058; doi: https://doi.org/10.1101/2021.12.21.21268058
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
Effectiveness of CoronaVac, ChAdOx1, BNT162b2 and Ad26.COV2.S among individuals with prior SARS-CoV-2 infection in Brazil
Thiago Cerqueira-Silva, Jason R. Andrews, Viviane S. Boaventura, Otavio T. Ranzani, Vinicius de Araújo Oliveira, Enny S Paixão, Juracy Bertoldo Júnior, Tales Mota Machado, Matt D.T. Hitchings, Murilo Dorion, Margaret L Lind, Gerson O. Penna, Derek A.T. Cummings, Natalie E Dean, Guilherme Loureiro Werneck, Neil Pearce, Mauricio L. Barreto, Albert I. Ko, Julio Croda, Manoel Barral-Netto
medRxiv 2021.12.21.21268058; doi: https://doi.org/10.1101/2021.12.21.21268058

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Infectious Diseases (except HIV/AIDS)
Subject Areas
All Articles
  • Addiction Medicine (430)
  • Allergy and Immunology (756)
  • Anesthesia (221)
  • Cardiovascular Medicine (3294)
  • Dentistry and Oral Medicine (364)
  • Dermatology (279)
  • Emergency Medicine (479)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (1171)
  • Epidemiology (13376)
  • Forensic Medicine (19)
  • Gastroenterology (899)
  • Genetic and Genomic Medicine (5153)
  • Geriatric Medicine (482)
  • Health Economics (783)
  • Health Informatics (3269)
  • Health Policy (1140)
  • Health Systems and Quality Improvement (1190)
  • Hematology (431)
  • HIV/AIDS (1017)
  • Infectious Diseases (except HIV/AIDS) (14629)
  • Intensive Care and Critical Care Medicine (913)
  • Medical Education (477)
  • Medical Ethics (127)
  • Nephrology (523)
  • Neurology (4925)
  • Nursing (262)
  • Nutrition (730)
  • Obstetrics and Gynecology (883)
  • Occupational and Environmental Health (795)
  • Oncology (2524)
  • Ophthalmology (724)
  • Orthopedics (281)
  • Otolaryngology (347)
  • Pain Medicine (323)
  • Palliative Medicine (90)
  • Pathology (543)
  • Pediatrics (1302)
  • Pharmacology and Therapeutics (550)
  • Primary Care Research (557)
  • Psychiatry and Clinical Psychology (4212)
  • Public and Global Health (7504)
  • Radiology and Imaging (1706)
  • Rehabilitation Medicine and Physical Therapy (1013)
  • Respiratory Medicine (980)
  • Rheumatology (480)
  • Sexual and Reproductive Health (497)
  • Sports Medicine (424)
  • Surgery (548)
  • Toxicology (72)
  • Transplantation (236)
  • Urology (205)